Week 24 – 10 June 2022
#01 👩⚕️⚕️🩺 | unprecedented r&d: all patients in drug trial are in remission with new rectal cancer drug.
A jaw-dropping result from a phase II trial at the Memorial Sloan Kettering Cancer Center & Yale University (sponsored by GlaxoSmithKline) has been achieved from a small clinical trial (18 patients) that led to all subjects being now in remission from rectal cancer that had been diagnosed at stage II or III.
Keep reading with a 7-day free trial
Subscribe to 10 links in 10 minutes to keep reading this post and get 7 days of free access to the full post archives.